Use of PET scans in Medicare highest for lymphoma, lung cancer

Researchers looking at the use of diagnostic imaging for cancer patients covered by Medicare between the years 1999 and 2006 found a significant increase in the use of PET scans, with two types of cancer at the top: lung cancer and non-Hodgkin's lymphoma (NHL).

Additionally, the use of CT scans increased in all these cancer types with the exception of NHLs.

Hand in hand with this increase in use of diagnostic imaging scans is costs per beneficiary with cancer, which, according to the study's authors, had a tendency to double each year.

CONCLUSIONS

Pressed to reach conclusions over the increase, the authors wrote, "It is unclear whether the rapid increase in use of advanced imaging is a result of the novelty of the technologies, better outcomes, or a shift to new revenue sources after the enactment of the Medicare Prescription Drug, Improvement, and Modernization Act."

PUBLICATIONS

This study was published in the April 28 2010 issue of the Journal of the American Medical Association (JAMA).

By Ross Bonander

Source: JAMA

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap